Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 25


FOXA1 inhibits prostate cancer neuroendocrine differentiation.

Kim J, Jin H, Zhao JC, Yang YA, Li Y, Yang X, Dong X, Yu J.

Oncogene. 2017 Jul 13;36(28):4072-4080. doi: 10.1038/onc.2017.50. Epub 2017 Mar 20.


Elevated expression of growth-regulated oncogene-alpha in tumor and stromal cells predicts unfavorable prognosis in pancreatic cancer.

Lian S, Zhai X, Wang X, Zhu H, Zhang S, Wang W, Wang Z, Huang J.

Medicine (Baltimore). 2016 Jul;95(30):e4328. doi: 10.1097/MD.0000000000004328.


SPOP Promotes Ubiquitination and Degradation of the ERG Oncoprotein to Suppress Prostate Cancer Progression.

Gan W, Dai X, Lunardi A, Li Z, Inuzuka H, Liu P, Varmeh S, Zhang J, Cheng L, Sun Y, Asara JM, Beck AH, Huang J, Pandolfi PP, Wei W.

Mol Cell. 2015 Sep 17;59(6):917-30. doi: 10.1016/j.molcel.2015.07.026. Epub 2015 Sep 3.


Prostate cancer and neuroendocrine differentiation: more neuronal, less endocrine?

Grigore AD, Ben-Jacob E, Farach-Carson MC.

Front Oncol. 2015 Mar 3;5:37. doi: 10.3389/fonc.2015.00037. eCollection 2015. Review.


CSF1 receptor targeting in prostate cancer reverses macrophage-mediated resistance to androgen blockade therapy.

Escamilla J, Schokrpur S, Liu C, Priceman SJ, Moughon D, Jiang Z, Pouliot F, Magyar C, Sung JL, Xu J, Deng G, West BL, Bollag G, Fradet Y, Lacombe L, Jung ME, Huang J, Wu L.

Cancer Res. 2015 Mar 15;75(6):950-62. doi: 10.1158/0008-5472.CAN-14-0992. Epub 2015 Mar 3.


Androgen receptor splice variants in the era of enzalutamide and abiraterone.

Nakazawa M, Antonarakis ES, Luo J.

Horm Cancer. 2014 Oct;5(5):265-73. doi: 10.1007/s12672-014-0190-1. Epub 2014 Jul 22. Review.


Androgen-deprivation therapy-induced aggressive prostate cancer with neuroendocrine differentiation.

Lipianskaya J, Cohen A, Chen CJ, Hsia E, Squires J, Li Z, Zhang Y, Li W, Chen X, Xu H, Huang J.

Asian J Androl. 2014 Jul-Aug;16(4):541-4. doi: 10.4103/1008-682X.123669. Review.


The Chemokine CXCL8 in Carcinogenesis and Drug Response.

Gales D, Clark C, Manne U, Samuel T.

ISRN Oncol. 2013 Oct 9;2013:859154. doi: 10.1155/2013/859154. Review.


The molecular basis for ethnic variation and histological subtype differences in prostate cancer.

Zong Y, Goldstein AS, Huang J.

Sci China Life Sci. 2013 Sep;56(9):780-7. doi: 10.1007/s11427-013-4522-0. Epub 2013 Jul 13. Review.


Chemokines and chemokine receptors as promoters of prostate cancer growth and progression.

Salazar N, Castellan M, Shirodkar SS, Lokeshwar BL.

Crit Rev Eukaryot Gene Expr. 2013;23(1):77-91. Review.


Neuroendocrine differentiation of prostate cancer.

Li Z, Chen CJ, Wang JK, Hsia E, Li W, Squires J, Sun Y, Huang J.

Asian J Androl. 2013 May;15(3):328-32. doi: 10.1038/aja.2013.7. Epub 2013 Mar 18. No abstract available.


Molecular pathology of prostate cancer revealed by next-generation sequencing: opportunities for genome-based personalized therapy.

Huang J, Wang JK, Sun Y.

Curr Opin Urol. 2013 May;23(3):189-93. doi: 10.1097/MOU.0b013e32835e9ef4. Review.


Pathogenesis of prostatic small cell carcinoma involves the inactivation of the P53 pathway.

Chen H, Sun Y, Wu C, Magyar CE, Li X, Cheng L, Yao JL, Shen S, Osunkoya AO, Liang C, Huang J.

Endocr Relat Cancer. 2012 May 24;19(3):321-31. doi: 10.1530/ERC-11-0368. Print 2012 Jun.


Loss of TGF-β responsiveness in prostate stromal cells alters chemokine levels and facilitates the development of mixed osteoblastic/osteolytic bone lesions.

Li X, Sterling JA, Fan KH, Vessella RL, Shyr Y, Hayward SW, Matrisian LM, Bhowmick NA.

Mol Cancer Res. 2012 Apr;10(4):494-503. doi: 10.1158/1541-7786.MCR-11-0506. Epub 2012 Jan 30.


Recent advances in underlying pathologies provide insight into interleukin-8 expression-mediated inflammation and angiogenesis.

Qazi BS, Tang K, Qazi A.

Int J Inflam. 2011;2011:908468. doi: 10.4061/2011/908468. Epub 2011 Dec 22.


Skp2 overexpression is associated with loss of BRCA2 protein in human prostate cancer.

Arbini AA, Greco M, Yao JL, Bourne P, Marra E, Hsieh JT, di Sant'agnese PA, Moro L.

Am J Pathol. 2011 May;178(5):2367-76. doi: 10.1016/j.ajpath.2011.01.050.


PC3 is a cell line characteristic of prostatic small cell carcinoma.

Tai S, Sun Y, Squires JM, Zhang H, Oh WK, Liang CZ, Huang J.

Prostate. 2011 Nov;71(15):1668-79. doi: 10.1002/pros.21383. Epub 2011 Mar 22.


Prognostic value and function of KLF4 in prostate cancer: RNAa and vector-mediated overexpression identify KLF4 as an inhibitor of tumor cell growth and migration.

Wang J, Place RF, Huang V, Wang X, Noonan EJ, Magyar CE, Huang J, Li LC.

Cancer Res. 2010 Dec 15;70(24):10182-91. doi: 10.1158/0008-5472.CAN-10-2414.


Neuroendocrine differentiation in prostate cancer.

Sun Y, Niu J, Huang J.

Am J Transl Res. 2009 Feb 5;1(2):148-62.


CXC receptor-1 silencing inhibits androgen-independent prostate cancer.

Shamaladevi N, Lyn DA, Escudero DO, Lokeshwar BL.

Cancer Res. 2009 Nov 1;69(21):8265-74. doi: 10.1158/0008-5472.CAN-09-0374. Epub 2009 Oct 27.

Supplemental Content

Support Center